Esperion Therapeutics, Inc.’s ESPR share price has dipped by 6.66%, which has investors questioning if this is right time to buy.

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi ...

Six posters presented at the American Association for Cancer Research (AACR) annual meetingAppointment of Dr. Sabeen Mekan as Senior Vice President, Clinical DevelopmentReported $321.6 million in cash ...

Discover Zymeworks' Q1 2025 earnings insights: strong revenue growth, pipeline advancements, and financial stability through 2027.

DelveInsight’s, "Neurofibrosarcoma Pipeline Insight 2025,” report provides comprehensive insights about 15+ companies and 15+ ...

In April 2025, our partner Jazz announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of ...

The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, ...

AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their HER2-directed antibody drug ...

Afatinib has broad activity against EGFR mutations. However, the approval for uncommon mutations was based on data from 38 ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSNKY) announced Wednesday that Enhertu, their jointly developed ...

Treatment with an Enhertu regimen significantly improved pathologic complete responses for patients with high-risk ...